Neuroprotection for Parkinson's disease: prospects and promises.
Olanow
C Warren
CW
Schapira
Anthony H V
AH
Agid
Yves
Y
D000662:Amphetamines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D051100:Glial Cell Line-Derived Neurotrophic Factor; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use*
D000662:Amphetamines; C495039:GDNF protein, human; D051100:Glial Cell Line-Derived Neurotrophic Factor; D008996:Monoamine Oxidase Inhibitors; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D012642:Selegiline; C017861:desmethylselegiline